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Abstract
There are almost two million people in the United Kingdom living with sight loss,
including around 360,000 people who are registered as blind or partially
sighted. Sight threatening diseases, such as diabetic retinopathy and age
related macular degeneration have contributed to the 40% increase in
outpatient attendances in the last decade but are amenable to early detection
and monitoring. With early and appropriate intervention, blindness may be
prevented in many cases.
 
Ophthalmic imaging provides a way to diagnose and objectively assess the
progression of a number of pathologies including neovascular (“wet”)
age-related macular degeneration (wet AMD) and diabetic retinopathy. Two
methods of imaging are commonly used: digital photographs of the fundus (the
‘back’ of the eye) and Optical Coherence Tomography (OCT, a modality that
uses light waves in a similar way to how ultrasound uses sound waves).
Changes in population demographics and expectations and the changing
pattern of chronic diseases creates a rising demand for such imaging.
Meanwhile, interrogation of such images is time consuming, costly, and prone
to human error. The application of novel analysis methods may provide a
solution to these challenges.
 
This research will focus on applying novel machine learning algorithms to
automatic analysis of both digital fundus photographs and OCT in Moorfields
Eye Hospital NHS Foundation Trust patients.
 
Through analysis of the images used in ophthalmology, along with relevant
clinical and demographic information, Google DeepMind Health will investigate
the feasibility of automated grading of digital fundus photographs and OCT and
provide novel quantitative measures for specific disease features and for
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provide novel quantitative measures for specific disease features and for
monitoring the therapeutic success.
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Background
Age-related macular degeneration (AMD) is a degenerative reti-
nal disease that can cause irreversible visual loss (Bressler, 2004). 
It is the leading cause of blindness in Europe and North America 
and accounts for over half of partially sighted or legally blind cer-
tifications in the UK (Bunce, 2010). Neovascular (“wet”) AMD 
is an advanced form of macular degeneration that historically has 
accounted for the majority of vision loss related to AMD. It is 
characterised by abnormal blood vessel growth that can result in 
hemorrhage, fluid exudation and fibrosis, and thus to local macular 
damage and ultimately vision loss (Owen, 2012).
Diabetic retinopathy (DR) is the leading cause of blindness in 
working age populations in the developed world (Cheung, 2010). 
It is estimated that up to 50% of people with proliferative DR 
(characterised by neovascularisation) who do not receive timely 
treatment will become legally blind within 5 years (Shaw, 2010). 
Although up to 98% of severe visual loss due to DR can be pre-
vented with early detection and treatment, once it has progressed 
vision loss is often permanent (Kollias, 2010). Indeed, 4,200 
people in England every year are at risk of blindness caused by 
diabetic retinopathy and there are 1,280 new cases of blindness 
caused by diabetic retinopathy (Scanlon, 2008).
To diagnose these conditions and monitor their progression (and 
response to treatment) the presence and precise location of the 
lesions must be determined. Two imaging modalities are com-
monly used for this purpose: digital photographs of the fundus (the 
‘back’ of the eye) and Optical Coherence Tomography (OCT, a 
modality that uses light waves in a similar way to how ultrasound 
uses sound waves) (Huang, 1991).
Clinics such as these have generated very large datasets of both 
digital fundus and OCT images. They are also very busy; oph-
thalmology clinics often have long waits and average times to 
urgent first treatments can be greater than two weeks in the busiest 
clinics.
Machine learning algorithms make use of the rich, varied datasets 
to find high dimensional interactions between multiple data points 
(Murphy, 2012). Most machine learning methods can be thought 
of as a form of statistics. Some algorithms look for patterns in 
the data, identifying subgroups within the full sample (known as 
clustering). Others rely on specific clinical information against 
which the algorithm compares its predictions and adjusts accord-
ingly (supervised learning).
There have been significant recent advances in the field of machine 
learning demonstrating algorithms able to learn how to accom-
plish tasks without instruction (Mnih, 2015; Silver, 2016). Recent 
healthcare applications of such algorithms have shed light on 
complex genetic interactions in autism (Uddin, 2014) and monitor-
ing of physiological observations in intensive care (Clifton, 2013).
This study aims to combine traditional statistical methodology 
and machine learning algorithms to achieve automatic grading 
and quantitative analysis of both digital fundus photograph and 
OCT in Moorfields Eye Hospital NHS Foundation Trust patients 
(London, UK). Moorfields Eye Hospital is the leading provider of 
eye health services in the UK and a world-class centre of excellence 
for ophthalmic research and education. Should the research be suc-
cessful, implementation of the outcomes would improve patient 
access to treatment and ease pressures on time and resources in 
ophthalmology clinics.
Aims and objectives
Primary objective
1.1
Exploratory study: investigate whether computer algorithms can 
detect and classify pathological features on eye imaging, including 
fundus digital photographs and OCT.
Secondary objectives
If the exploratory study is successful:
2.1
To provide novel image analysis algorithms to identify and quantify 
specific pathological features in eye imaging, using validated meth-
ods and expert clinical consensus.
2.2
To provide quantitative measurements disease progression, severity 
and to monitor the therapeutic success over time.
Study design
This is a retrospective, non-interventional exploratory study. 
Analyses performed in the study will be on fully anonymised (to 
achieve the primary objective) and pseudonymised (to achieve the 
secondary objective 2.2) retinal images (including fundus images 
and OCT). These images will contain no patient identifiable 
information.
Inclusion criteria
All patients attending Moorfields Eye Hospital NHS Foundation 
Trust sites between 01/01/2007 and 29/02/2016, and who had 
digital retinal imaging (including fundus digital photographs and 
OCT) as part of their routine clinical care, will be eligible for inclu-
sion in this study.
Exclusion criteria
Hard copy examinations (i.e. physical photograph copies prior to 
digital storage) will be ineligible, and will be excluded by the nature 
of the original service evaluation requests from the Moorfields 
team. Data from patients who have previously manually requested 
that their data should not be shared, even for research purposes in 
anonymised form, and have informed Moorfields Eye Hospital of 
this, will be ineligible and removed by Moorfields Eye Hospital 
staff before research begins.
Sample size
Approximately 1 million examinations meet the above criteria.
Most recent machine learning algorithms benefit from large 
datasets on which to train (tens to hundreds of thousands of data 
instances (Silver, 2016)). Across all machine learning applications 
the predictive power (as percentage of data instances correctly 
classified) of the algorithm depends on the size and quality of the 
dataset.
Page 3 of 8
F1000Research 2016, 5:1573 Last updated: 25 DEC 2016
The sample size is informed by the existing literature and by 
DeepMind’s previous work in the field of machine learning (Mnih, 
2015; Silver, 2016). Today’s most powerful deep neural networks 
can have millions or billions of parameters, so large amounts of 
data are needed to automatically infer those parameters during 
learning. Most problems in the medical domain are highly com-
plex as they arise as an interplay of many clinical, demographic, 
behavioural and environmental factors that are correlated in 
non-trivial ways. This is even more true for state-of-the art deep 
learning methodologies that are expected to give the best results 
(Szegedy, 2014).
Data
For all patients meeting inclusion/exclusion criteria the follow-
ing electronic health record data will be required to complete this 
project successfully:
(1) Digital Fundus Photographs
(2) Digital OCT images
In addition to image data, the anonymised dataset will contain 
additional information required to train an algorithm (objective 1.1):
•  Demographic information shown to be associated with 
eye disease. This is because the retina differs by features 
such as age, as do the likelihoods, manifestations and
progression of specifc disease states.
•  Primary and secondary diagnostic labels describing 
what pathology is in the image (e.g., wet AMD, diabetic 
retinopathy) and the associated severity (e.g., grade of 
retinopathy/maculopathy in diabetic retinopathy).
•  Treatment information describing aspects of management 
alongside pathology information and clinical data such 
as visual acuity.
• Model of imaging device.
A second dataset will be pseudonymised to allow further investiga-
tion of disease progression and treatment effects. This will include 
the above information, and add temporal information allowing 
pseudonymised data to be joined over time with knowledge of the 
elapsed time between each:
•  Time elapsed between each data point and the first visit 
in weeks (Sunday to Sunday).
•  The dates of each scan will be removed so it will be 
impossible to identify an individual date or year of 
patient’s birth.
The anonymisation and pseudonymisation procedures adopted will 
remove any information not specified to further avoid transfer of 
patient identifiable information. All anonymisation and pseudo-
nymisation will be formally checked by Moorfields Eye Hospital 
staff before transfer.
Algorithm development
In order to develop the algorithm, Google DeepMind will work 
with the eye images, split by the known diagnoses, using machine 
learning and Artificial Intelligence techniques including but not 
limited to: supervised and semi-supervised convolutional neural 
networks, recurrent neural networks, unsupervised clustering, rein-
forcement learning (Murphy, 2012).
For a selection of images additional manual labels will be pro-
duced by experts to allow investigation of the clinical benefit that 
can be achieved through the use of machine learning in eye imaging. 
Pathological and anatomical features will be annotated by trained 
graders at Moorfields Eye Hospital and overseen by a consultant 
ophthalmologist with over 10 years of experience.
Statistical analysis
Descriptive statistics will be used to describe specific pathological 
features extracted by the model on retinal images, both continuous 
and categorical (e.g. presence and size of an abnormality), and to 
compare them to an expert references.
In addition we will analyse the outcomes against recent Moorfields 
audit data on human performance to further understand the poten-
tial impacts of the model in clinical practice.
Data protection
Anonymisation and pseudonymisation
This study requires existing retrospective data only; no prospective 
data are needed nor will be collected from patients, hospitals or 
healthcare workers. No direct patient contact will occur and neces-
sary data will be anonymised or pseudonymised from this source 
dataset.
Anonymisation and pseudonymisation of all image files and 
clinical information is performed and validated by Moorfields Eye 
Hospital staff at Moorfields Eye Hospital. No patient identifiable 
data will be transferred to Google DeepMind.
During validation of the anonymisation procedure it was noted 
that the current anonymisation tool (TopCon IDConvert) in use at 
Moorfields had the potential to leave information that may identify 
the patient in a small number of datasets. DeepMind collaborators 
worked with Moorfields Eye Hospital IT team to develop an ano-
nymisation script that reliably deletes all of these information in 
a second step. This new script will be used in the project and will 
be run by Moorfields Eye Hospital NHS Foundation Trust staff at 
Moorfields Eye Hospital. Google DeepMind will not have access to 
patient identifiable information at any time.
Data storage
Google DeepMind Health has developed and established a state-
of-the-art secure patient information handling service utilising 
Common Criteria EAL4 compliant firewalls and on-disk encryp-
tion (using Advanced Encryption Standard with a 256-bit key) 
of all research data, all housed within an ISO 27001 compliant 
data centre. After anonymisation data will be transferred to our 
London, UK data centre. This data handling facility conforms to 
NHS HSCIC Information Governance Statement of Compliance 
Toolkit (formally assessed at level 3).
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Access will be granted by the custodian of data and no other mem-
bers of the team. Only those working directly on the data in a 
research capacity will have access.
Data destruction
The data sharing agreement between Google DeepMind and 
Moorfields Eye Hospital NHS Foundation Trust lasts for 5 years. 
After this period the agreement will be reviewed should future 
work seek to build on this project. After the data sharing agreement 
expires all data used in the study will be destroyed. No modification 
will be made based on the data after destruction.
Data destruction will involve the deletion of the encryption/decryp-
tion keys for all project volumes, and 8-way random data write to 
all physical disks within the Google DeepMind Health data infra-
structure. A certificate of destruction will be provided to the Trust.
The algorithms developed during the study will not be destroyed. 
Google DeepMind Health knows of no way to recreate the patient 
images transferred from the algorithms developed. No patient iden-
tifiable data will be included in the algorithms.
Ethical considerations
Ethical approvals
The research on anonymised data received formal approval from 
the Moorfields Eye Hospital research and development office, 
responsible for approving studies working with anonymised data, 
on 16 Oct 2015 (reference 15/050).
The research on the pseudonymised dataset received formal 
Research Ethics Committee approval on 03 Jun 2016 (reference 
16/EE/0253). Health Research Authority approval for this is in 
progress and no research on pseudonymised data will begin until 
this is approved.
Consent
No patient will be approached directly and this work will include no 
direct patient contact. Only anonymised or pseudonymised retro-
spective data collected as part of routine clinical care are included. 
No patient identifiable data will be collected as part of this study. 
In such cases the ICO code of practice states that explicit consent is 
not generally required (ICO, 2012).
Adverse events
The project is non-interventional and does not involve any direct 
patient contact. We do not anticipate any change to patient 
management. For pseudonymised data should expert assessment 
during model validation highlight a clinical error this will be 
raised to the appropriate clinical team. The primary point of call 
for adverse events should they arise will be the Trust information 
governance lead, and the responsible clinical team at Moorfields 
Eye Hospital will be notified.
Monitoring
The study will be monitored both internally and externally. Inter-
nally Google DeepMind managers (TB, JL) will oversee and moni-
tor progress on a day-to-day basis, ensuring the protocol is adhered 
to and no compliance issues arise.
Clinical and methodological experts (PK, GR, RR) are working 
with Google DeepMind to further oversee the ethical, clinical and 
methodological considerations of the project and will advise on 
at least a weekly basis to ensure no deviation from the described 
protocol.
Externally the information governance team at the Moorfields Eye 
Hospital will be consulted before commencing data collection, 
and weekly thereafter to ensure no deviation from the described 
protocol.
Access
Google DeepMind has access to the required data to support 
the research aims of this study. To ensure compliance with the 
common law principle of data confidentiality, Google DeepMind 
will only receive anonymised or pseudonymised data from the 
Trust. DeepMind works with Moorfields Eye Hospital to ensure 
accuracy and clarity in the data to allow useful and consistent 
interpretation at all times.
Dissemination
The results will be disseminated through normal academic chan-
nels, initially focusing on conference proceedings and the indexed 
peer reviewed literature relevant to the fields of machine learning, 
artificial intelligence, ophthalmology and clinical research. Patient 
and Public Involvement representatives will be involved at each 
stage of the research.
Conclusion
We propose an exploratory study and initial testing of machine 
learning algorithms to analyse and quantify pathological and ana-
tomical features in eye images. The results will be compared to 
expert annotations.
Should development be successful we plan to submit additional 
applications for permission to refine the model if required and ulti-
mately investigate the performance in a clinical implementation 
setting.
Author contributions
All authors contributed to study design and methodology. JDF, 
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Thank you very much for the opportunity to review the manuscript by De Fauw and co-workers. The topic
is of great interest. Moorefields recently announced their research partnership with DeepMind Health. In
this manuscript the project plan is detailed. One million examinations (digital fundus photographs and
OCT scans) which met the inclusion criteria will be analysed using machine learning and Artificial
Intelligence techniques.
The authors did not specify why they did not include angiography as an additional imaging modality which
is usually used at baseline or at follow-up exams in patients with AMD and diabetic retinopathy. Please
add this information.
Since data security is an important issue to be discussed especially when evaluating such large data sets
the authors need to provide more information regarding patient consent. Does everyone who is examined
at Moorefields Eye Hospital give a general consent for evaluating their data? Patients are not specifically
informed about the project with DeepMind Health, aren't they? So data of patients are only excluded if
patients previously (independent of this project) requested that there data should not be shared.
Although there might be some risk regarding "data security" it outweighs the potential of earlier detection
and treatment of million of patients.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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There is a good introduction of the two main conditions, AMD and DR and their burden on public health.
 
Very little information on machine learning to convince the reader that the fundamental processes and
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Very little information on machine learning to convince the reader that the fundamental processes and
pieces of the jigsaw are already available to apply to AMD and DR or in simpler healthcare scenarios.
 
How does MEH plan to locate the ID of those who have given instructions for their images NOT to be
used?  Is there a database for this specific parameter?
 
Good attention to data security and data protection.
 
Not very much information on specific data outcomes expectations. Eg how detailed will be grading be of
a wet AMD lesion.
 
Overall, a novel concept and worth exploring as it will be able to replace human workforce if successful.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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